BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38085082)

  • 21. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    Davies DR; Redfield MM; Scott CG; Minamisawa M; Grogan M; Dispenzieri A; Chareonthaitawee P; Shah AM; Shah SJ; Wehbe RM; Solomon SD; Reddy YNV; Borlaug BA; AbouEzzeddine OF
    JAMA Cardiol; 2022 Oct; 7(10):1036-1044. PubMed ID: 36069809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis.
    Azevedo Coutinho MC; Cortez-Dias N; Cantinho G; Gonçalves S; Cunha N; Rodrigues T; Santos L; Conceição I; Agostinho J; Pinto FJ
    Amyloid; 2024 Mar; 31(1):32-41. PubMed ID: 37493395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.
    Treibel TA; Fontana M; Gilbertson JA; Castelletti S; White SK; Scully PR; Roberts N; Hutt DF; Rowczenio DM; Whelan CJ; Ashworth MA; Gillmore JD; Hawkins PN; Moon JC
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27511979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis.
    Ungericht M; Groaz V; Messner M; Schuetz T; Brunelli L; Zaruba MM; Lener D; Stocker E; Bauer A; Kroiss AS; Mayr A; Röcken C; Poelzl G
    Amyloid; 2024 Mar; 31(1):22-31. PubMed ID: 37530216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial scanning with
    Minutoli F; Di Bella G; Mazzeo A; Laudicella R; Gentile L; Russo M; Vita G; Baldari S
    J Nucl Cardiol; 2021 Oct; 28(5):1949-1957. PubMed ID: 31741327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality.
    Sperry BW; Vranian MN; Tower-Rader A; Hachamovitch R; Hanna M; Brunken R; Phelan D; Cerqueira MD; Jaber WA
    JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 1):234-242. PubMed ID: 28917675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.
    Bokhari S; Castaño A; Pozniakoff T; Deslisle S; Latif F; Maurer MS
    Circ Cardiovasc Imaging; 2013 Mar; 6(2):195-201. PubMed ID: 23400849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.
    Pilebro B; Suhr OB; Näslund U; Westermark P; Lindqvist P; Sundström T
    Ups J Med Sci; 2016; 121(1):17-24. PubMed ID: 26849806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac scintigraphy and echocardiography assessment in the diagnosis of transthyretin cardiac amyloidosis.
    Del Carmen Mallón Araujo M; Casas EAJ; Casas CAJ; Monzonis MAM; Morell ÁR; Núñez VP
    Int J Cardiovasc Imaging; 2024 Feb; 40(2):415-424. PubMed ID: 37943369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative
    Caobelli F; Braun M; Haaf P; Wild D; Zellweger MJ
    J Nucl Cardiol; 2020 Oct; 27(5):1456-1463. PubMed ID: 31538322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In the midst of a dangerous intersection with unclear therapeutic strategies: a challenging case of severe aortic stenosis.
    Gallone G; Landra F; D'Ascenzo F; Conrotto F; Casoni R; Bruno F; Omedè P; Alunni G; Andreis A; Vairo A; Giorgi M; Fava A; De Ferrari GM
    BMC Cardiovasc Disord; 2020 Jun; 20(1):261. PubMed ID: 32487051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Echocardiographic score for the screening of cardiac amyloidosis with positive 99m technetium pyrophosphate scintigraphy result.
    Nagai T; Horinouchi H; Hashimoto K; Ichiji T; Yoshioka K; Hashimoto J; Ikari Y
    Echocardiography; 2023 Jul; 40(7):634-641. PubMed ID: 37243310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.
    Yamaguchi S; Oda S; Kidoh M; Hayashi H; Takashio S; Usuku H; Nagayama Y; Nakaura T; Tsujita K; Hirai T; Aoki T
    Acad Radiol; 2024 Feb; 31(2):514-522. PubMed ID: 37775448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo.
    Arana-Achaga X; Goena-Vives C; Villanueva-Benito I; Solla-Ruiz I; Rengel Jimenez A; Gaspar TI; Urreta-Barallobre I; Barge-Caballero G; Seijas-Marcos S; Cabrera E; Garcia-Pavía P; Basurte Elorz MT; Ayestarán NM; Sierra LT; Robledo Iñarritu M; Lozano-Bahamonde A; Escolar-Perez V; Gómez-Ramírez C; Alzola E; Andrés RN; Francisco Matias JL; Limeres Freire J; Armengou Arxe A; Negre Busó M; Piqueras-Flores J; Martínez-Del Río J; Onaindia Gandarias JJ; Rodriguez Sanchez I; Querejeta Iraola R
    JACC Cardiovasc Imaging; 2023 Dec; 16(12):1567-1580. PubMed ID: 37389511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
    Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
    JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
    Lau ATC; DiDomenico RJ; Kim K
    Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.
    Glaudemans AW; van Rheenen RW; van den Berg MP; Noordzij W; Koole M; Blokzijl H; Dierckx RA; Slart RH; Hazenberg BP
    Amyloid; 2014 Mar; 21(1):35-44. PubMed ID: 24455993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction.
    Lo Presti S; Horvath SA; Mihos CG; Rajadhyaksha C; McCloskey V; Santana O
    Crit Pathw Cardiol; 2019 Dec; 18(4):195-199. PubMed ID: 31725511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transthyretin cardiac amyloidosis in patients after TAVR: clinical and echocardiographic findings and long term survival.
    Shimoni S; Zikri M; Haberman D; Livschitz S; Tshori S; Fabricant Y; Meledin V; Gandelman G; Goland S; George J
    ESC Heart Fail; 2021 Dec; 8(6):4549-4561. PubMed ID: 34704399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
    JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.